
China Set for Critical Orbital Refueling Test With 2 U.S. Satellites Watching Closely
Shijian-21 and Shijian-25 performed a series of maneuvers this past weekend, reaching a close distance of just two degrees of longitude from one another on Monday, according to space situational awareness company COMSPOC. The pair are set to meet on Wednesday for a docking procedure for China's first on-orbit refueling test in geostationary orbit (GEO), acting like a space gas station to extend the lifespan of satellites. China's satellites aren't alone, however, as two U.S. surveillance spacecraft are lurking nearby to watch it all happen, with the Pentagon fearing the technology could represent a significant milestone in China's space ambitions.
The two satellites were developed by the Shanghai Academy of Spaceflight Technology, a subsidiary of the China Aerospace Science and Technology Corporation. Shijian-25 launched in January while Shijian-21 lifted off earlier in 2021. Around a year after its launch, Shijian-21 docked with a defunct Chinese satellite, the Beidou-2 G2 navigation satellite, and towed it to the graveyard orbit above GEO, SpaceNews reported at the time.
Since then, Shijian-21 appeared to have run out of fuel—until it recently sprang back to life with maneuvers of its own to get closer to Shijian-25. It's likely the target of the in-orbit refueling test, in which Shijian-25 will attempt to transfer about 313 pounds (142 kilograms) of hydrazine to extend the satellite's life by eight years, according to Universe Today.
The refueling test has raised concerns in the U.S. about China's growing space capabilities, prompting officials to closely monitor the situation. Two surveillance satellites, USA 270 and USA 271, part of the Geosynchronous Space Situational Awareness Program, performed maneuvers of their own to approach the vicinity of the Chinese satellites, according to COMSPOC. 'While these U.S. assets aren't directly involved, their proximity adds complexity to the local SSA picture — and raises strategic awareness concerns,' the company wrote on X.
The U.S. has previously carried out in-orbit refueling tests of its own. In 2019, Northrop Grumman refueled a satellite in space to extend its lifespan by five years, becoming the first company to do so. The U.S. Space Force is also preparing its own set of orbital refueling tests, known as Tetra-5 and Tetra-6, using hardware from Northrop Grumman and other commercial suppliers.
For now, the U.S. will stick to watching its space rival carry out the orbital maneuver from a safe distance.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
18 hours ago
- Bloomberg
Ship-Signal Spoofing Spreads to Russia's Pacific Kozmino Port
Exports of crude from the Kozmino oil terminal on Russia's Pacific coast have become harder to track in recent days, after ships' automated position signals began to suffer electronic interference. The process, known as spoofing, sees signals sent between ships and the satellites used for global positioning systems swamped by false transmissions, which lead to vessels reporting themselves to be in impossible positions or moving at infeasible speeds.


Medscape
19 hours ago
- Medscape
Low FT3 Levels Predict Risk for Nerve Damage in Diabetes
TOPLINE: In euthyroid patients with type 2 diabetes (T2D), relatively higher free triiodothyronine (FT3) levels within the normal range were linked to a lower risk for diabetic peripheral neuropathy and better nerve function. METHODOLOGY: In euthyroid patients with T2D, lower FT3 levels within the normal range can worsen glucose and lipid metabolism and increase the risk for nephropathy and retinopathy, but the association of FT3 levels with peripheral neuropathy remains unclear. Researchers in China examined the relationship between FT3 levels and diabetic peripheral neuropathy in 1422 euthyroid patients with T2D (mean age, 58.04 years; 33.97% women) who underwent electromyography during hospitalization. Participants were considered euthyroid if their thyroid-stimulating hormone level was 0.25-5.5 IU/mL, free thyroxine level was 9.0-25.5 pmol/L, and FT3 level was 2.5-7.0 pmol/L. A diagnosis of diabetic peripheral neuropathy was made in those who showed neuropathic symptoms (neuropathic pain, paresthesias, numbness, sensory distortion, unsteadiness, or falls) and signs (pain sensation abnormalities, vibration sensation abnormalities, loss of the ankle reflex, touch/pressure sensation abnormalities, or temperature sensation abnormalities) during or after confirmed diabetes diagnosis. Nerve conduction studies of the distal limbs (median, ulnar, common peroneal, sural, and superficial peroneal nerves) were conducted in all participants, and distal motor and sensory nerve latencies, action potential amplitudes, and conduction velocities of motor and sensory nerves were recorded. TAKEAWAY: Among all participants with T2D, the 519 who were diagnosed with diabetic peripheral neuropathy showed significantly lower serum FT3 levels than those without the condition (P < .001). The risk for diabetic peripheral neuropathy was reduced in participants with FT3 levels between 4.3 and 4.7 pmol/L (odds ratio [OR], 0.57; 95% CI, 0.39-0.81) and 4.7 and 7.0 pmol/L (OR, 0.33; 95% CI, 0.21-0.52) compared with those with FT3 levels between 2.5 and 3.8 pmol/L. Participants with neuropathy had slower, weaker nerve responses and longer latencies than those without, with higher FT3 levels in patients with diabetic peripheral neuropathy being linked to faster nerve conduction and shorter latencies. A Mendelian randomization analysis using the ThyroidOmics Consortium and the UK Biobank genome-wide association study data also indicated a causal relationship between low FT3 levels and the risk for diabetic peripheral neuropathy (inverse variance weighted β = -0.655; P = .035). IN PRACTICE: 'Within the normal range, a relatively high level of FT3 (> 4.3 pmol/L) was associated with a reduced risk of DPN [diabetic peripheral neuropathy]. Thyroid hormones may be beneficial for patients with DPN if their FT3 levels are near the low end of the normal range,' the authors of the study wrote. SOURCE: This study was led by Bing'er Xu, Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China. It was published online in the Journal of Clinical Endocrinology and Metabolism. LIMITATIONS: This study was limited by its single-center design and focused on hospitalized patients with T2D in Shanghai. It measured only specific peripheral nerves' conduction parameters. The Mendelian randomization analysis was conducted only in Europeans, requiring validation in other ethnic populations. DISCLOSURES: This study received support from the National Science and Technology Major Project, the National Natural Science Foundation of China, the Science and Technology Commission of Shanghai Municipality, and other sources. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
19 hours ago
- Yahoo
Asia-Pacific Molecular Oncology Diagnostics Market Research 2024-2033
The Asia-Pacific molecular oncology diagnostics market, valued at $513.6 million in 2024, is projected to surge to $1.54 billion by 2033 with a CAGR of 12.99%. Key technologies like digital PCR, liquid biopsy, and next-generation sequencing are driving growth amid rising cancer rates in China, India, and Japan. While high costs and a shortage of skilled professionals challenge expansion, collaborations and innovations are enhancing molecular diagnostic adoption. Strategic efforts, including AI, reimbursement standardization, and genomic literacy programs, aim to advance precision oncology in the APAC region, addressing barriers and harnessing growth opportunities. Asia-Pacific Molecular Oncology Diagnostics Market Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Molecular Oncology Diagnostics Market: Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033" has been added to Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1.54 billion by 2033. Digital PCR, liquid biopsy, and next-generation sequencing (NGS) are the main technological factors propelling the APAC molecular cancer diagnostics market's explosive expansion. The need for earlier detection, more accurate therapy choices, and ultimately improved patient outcomes is being fuelled by the rising incidence of cancer in nations like China, India, and Japan. The market for molecular oncology diagnostics in Asia-Pacific (APAC) is expected to grow quickly as healthcare systems in China, India, Japan, and Southeast Asia place a greater emphasis on precision medicine. The use of molecular assays, especially next-generation sequencing (NGS), digital PCR, and liquid biopsy, is growing because they can more precisely and early identify genetic changes linked to cancer than conventional techniques. The demand for these cutting-edge instruments is being driven by the rising prevalence of colorectal, lung, and breast cancers as well as increased patient and physician awareness. Clinical adoption is also being accelerated by national genomics programs, companion diagnostics recommendations, and public and private investments in laboratory infrastructure. High test prices, disjointed regulatory procedures, and a lack of qualified bioinformaticians and molecular technologists, particularly in lower-income regions, continue to be major participants are establishing strategic alliances, increasing locally produced goods, and putting in place training initiatives to develop technological know-how in order to overcome these obstacles. Automated high-throughput platforms are being implemented in the meanwhile to expedite processes and shorten turnaround times. In the future, the combination of AI-powered bioinformatics, increased reimbursement coverage, and more robust data-security frameworks will be essential for promoting long-term industry expansion. By providing more individualised, efficient cancer treatment in a variety of healthcare settings, the APAC molecular oncology diagnostics market is anticipated to take a sizable chunk of the worldwide precision oncology market by 2030. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $513.6 Million Forecasted Market Value (USD) by 2033 $1542 Million Compound Annual Growth Rate 12.9% Regions Covered Asia Pacific APAC Molecular Oncology Diagnostics Market Trends, Drivers & Challenges: Market Trends Technological Advancements: Rapid uptake of next generation sequencing (NGS), digital PCR and liquid biopsies (ctDNA/ctC) for non invasive, real time cancer monitoring. Consolidation & Partnerships: Increased M&A activity reshaping the competitive landscape, with major lab and diagnostics players acquiring or partnering on advanced platforms. Companion Diagnostics Integration: Growing adoption of CDx assays to match patients with targeted therapies, supported by evolving regulatory guidelines in key markets like Japan and Australia. Automation & High Throughput Platforms: Deployment of automated systems in both clinical and research labs to boost efficiency and sample throughput. Market Drivers Rising Cancer Incidence: Surging rates of breast, lung and colorectal cancers across China, India, Japan and Southeast Asia fueling demand for precise diagnostics. Precision Medicine Push: Strategic shift toward personalized oncology, with payers and providers investing in genotype-guided treatment pathways. Government & Public-Private Initiatives: National programs and partnerships underwriting infrastructure expansion, including genomics missions and companion diagnostics guidelines. Healthcare Infrastructure Investments: Capital inflows into lab upgrades, biotech R&D and specialized cancer centers enhancing regional capacity. Market Challenges High Cost of Testing: Advanced molecular assays remain expensive, limiting penetration in lower income APAC markets. Regulatory Complexity: Fragmented and evolving approval pathways across different countries delay product launches. Skilled Workforce Shortage: Insufficient numbers of trained molecular technologists and bioinformaticians impede broader clinical rollout. Data Security & Privacy: Handling of sensitive genomic and patient data raises compliance and cybersecurity concerns. Market Segmentation: Cancer Type Solid Tumors Hematologic Malignancies End User Hospitals and Diagnostic Centers Reference Laboratories Pharmaceutical and Biotechnology Companies Academic and Research Institutes Region Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Molecular Oncology Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900